Advertisement
U.S. markets close in 5 hours 50 minutes
  • S&P 500

    5,250.79
    +2.30 (+0.04%)
     
  • Dow 30

    39,758.08
    -2.00 (-0.01%)
     
  • Nasdaq

    16,389.05
    -10.47 (-0.06%)
     
  • Russell 2000

    2,119.39
    +5.04 (+0.24%)
     
  • Crude Oil

    82.38
    +1.03 (+1.27%)
     
  • Gold

    2,229.30
    +16.60 (+0.75%)
     
  • Silver

    24.70
    -0.05 (-0.19%)
     
  • EUR/USD

    1.0811
    -0.0019 (-0.17%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2641
    +0.0003 (+0.02%)
     
  • USD/JPY

    151.3030
    +0.0570 (+0.04%)
     
  • Bitcoin USD

    71,105.66
    +2,006.73 (+2.90%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,959.90
    +27.92 (+0.35%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Erasca to Present at the Bank of America Securities 2023 Health Care Conference

Erasca, Inc.
Erasca, Inc.

SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in a fireside chat on Tuesday, May 9, 2023, at 2:20 pm Pacific Time at the Bank of America Securities 2023 Health Care Conference, which is being held at the Encore Hotel, Las Vegas, NV. Management will also participate in one-on-one investor meetings.

An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Source: Erasca, Inc.


Advertisement